An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Labcorp First National Laboratory to Offer Monkeypox Test
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Labcorp (NYSE: LH) announced it will begin testing for monkeypox using the CDC's orthopoxvirus test, enhancing access to testing during the ongoing outbreak. Labcorp is the first national laboratory to offer this PCR test and aims to increase testing capacity to 10,000 tests per week, doubling the current capacity. Initially performed in North Carolina, testing can expand nationwide if necessary. The public will need to consult healthcare providers for sample collection and testing initiation. This initiative underscores Labcorp's commitment to public health.
Positive
First national laboratory to offer monkeypox PCR testing.
Increased testing capacity up to 10,000 tests per week.
Enhanced access to testing in communities nationwide.
Negative
None.
Expands Access to Communities Across the United States
BURLINGTON, N.C.--(BUSINESS WIRE)--
Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.
Photo courtesy of Labcorp
Labcorp is the first national laboratory to offer this polymerase chain reaction (PCR) test, which it verified for the CDC, and the first to launch a more automated assay option.
“Labcorp appreciates the opportunity to support the CDC in its efforts to keep the public safe and manage the monkeypox outbreak,” said Dr. Brian Caveney, chief medical officer and President of Labcorp Diagnostics. “We will initially perform all monkeypox testing in our main North Carolina lab and have the capacity to expand to other locations nationwide should the need arise.”
Labcorp will offer the testing at its largest laboratory in the United States and has the ability to accept specimens from its customers, as well as overflow from public laboratories, from across the U.S. using its significant transportation and logistics capabilities. Eventually, Labcorp will have the ability to increase capacity up to 10,000 tests per week, which will double the current capacity provided through CDC’s Laboratory Response Network (LRN). This development will facilitate increased testing by leveraging established relationships between Labcorp and the clinics, hospitals, and health care providers it serves. Labcorp will use electronic laboratory reporting (ELR) to report results to jurisdictions as outlined in the CDC reporting guidance.
The public will go to their health care provider for sample collection and to initiate the testing process; however, health care providers can order the orthopoxvirus test from Labcorp just as they normally would order other tests. This test is currently available on the Labcorp test menu.
CDC guidance is that anyone with a rash that looks like monkeypox should talk to their health care provider, even if they don’t think they had contact with someone who has monkeypox.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
